Mati Therapeutics

OverviewSuggest Edit

Mati Therapeutics is a company that develops a non-invasive sustained drug delivery platform. It utilizes a device called a punctal plug, which is inserted into a patient’s punctum. The platform is used to treat ocular diseases, mainly glaucoma.
HQAustin, TX, US

Latest Updates

Cybersecurity ratingCMore

Key People/Management at Mati Therapeutics

Robert Butchofsky

Robert Butchofsky

Chief Executive Officer
Christopher A. Muller

Christopher A. Muller

Chief Commercial Officer
Deepank Utkhede

Deepank Utkhede

Chief Scientific Officer
Cameron Nelson

Cameron Nelson

Chief Financial Officer
Show more

Mati Therapeutics Office Locations

Mati Therapeutics has offices in Austin and Burnaby
Austin, TX, US (HQ)
4317 Dunning Ln
Burnaby, CA
4475 Wayburne Dr
Show all (2)

Mati Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Mati Therapeutics total Funding

$1.6 m

Mati Therapeutics latest funding size

$165.03 k

Time since last funding

2 years ago
Mati Therapeutics's latest funding round in May 2019 was reported to be $165 k. In total, Mati Therapeutics has raised $1.6 m
Show all financial metrics

Mati Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Mati Therapeutics Online and Social Media Presence

Embed Graph

Mati Therapeutics News and Updates

JCRS Publication of Phase II Nepafenac Clinical Trial With Evolute® Sustained Drug Delivery System Demonstrates Significant Post-Op Pain Reduction in Cataract Surgery Patients

Mati Therapeutics Inc. (“Mati”) announced that a peer reviewed manuscript of a Phase II clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute® sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refracti…

Mati Therapeutics Announces Purchase of Rights From Novelion Therapeutics Inc.

Mati Therapeutics Inc. (“Mati”) announced that it has purchased all rights related to Mati’s Evolute Punctal Plug Delivery System (PPDS) from Novelion Therapeutics Inc. (“Novelion”). This purchase is part of Novelion’s voluntary liquidation process.

Mati Therapeutics Frequently Asked Questions

  • When was Mati Therapeutics founded?

    Mati Therapeutics was founded in 2012.

  • Who are Mati Therapeutics key executives?

    Mati Therapeutics's key executives are Robert Butchofsky, Christopher A. Muller and Deepank Utkhede.

  • Who are Mati Therapeutics competitors?

    Competitors of Mati Therapeutics include Equinox, Amorphex Therapeutics and Ocular Therapeutix.

  • Where is Mati Therapeutics headquarters?

    Mati Therapeutics headquarters is located at 4317 Dunning Ln, Austin.

  • Where are Mati Therapeutics offices?

    Mati Therapeutics has offices in Austin and Burnaby.

  • How many offices does Mati Therapeutics have?

    Mati Therapeutics has 2 offices.